( NEW ORLEANS--(BUSINESS WIRE)--Mar 26 2...)Two New Imaging Studies Show Higher Dose Lipitor Stopped the,Progression of Atherosclerosis,Health

NEW ORLEANS--(BUSINESS WIRE)--Mar 26, 2007 - Pfizer said today that results from two new imaging trials showed that higher dose Lipitor stopped the progression of atherosclerosis in patients with coronary heart disease or familial hypercholesterolemia (FH). The trials, which were designed to investigate the efficacy of the former investigational compound torcetrapib in combination with Lipitor compared to Lipitor alone, were presented today at the annual meeting of the American College of Cardiology.

In the Lipitor arm of the ILLUSTRATE and RADIANCE 1 trials, patients took an average Lipitor dose of 23 mg and 56 mg respectively and experienced halting of the progression of atherosclerosis. In the ILLUSTRATE trial, treatment with Lipitor resulted in plaque regression in the most diseased part of the coronary artery. In contrast in the Lipitor arm of RADIANCE 2 patients took a low average Lipitor dose of 13 mg and progression of atherosclerosis was observed.

"From a clinical perspective, what is remarkable in these studies is that Lipitor was able to stop the progression of disease, including the most difficult to treat FH patients studied in RADIANCE 1," said Professor John Kastelein, lead investigator for two of the trials, and professor of medicine and chairman of vascular medicine at the Academic Medical Center in Amsterdam. "These trials build on the effects seen with Lipitor in numerous imaging trials."

Lipitor is the only statin to have been studied in head-to-head imaging trials. In the ASAP and ARBITER trials, which measured changes in cIMT, high-risk patients who took Lipitor 80 mg experienced regression in atherosclerosis compared with patients who took other statins. In the REVERSAL trial, Lipitor patients experienced a halting of plaque progression compared with pravastatin, and Lipitor patients experienced a significant reduction in the plaque volume in the most diseased segments compa
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
2. Repligen Reports Positive Phase 2 Clinical Trial Results of Secretin for MRI Imaging of the Pancreas
3. Avid Announces Results of AV-1 Molecular Imaging Agent for Alzheimers Disease Presented at AD/PD Meeting
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
6. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
7. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
8. Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants
9. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
10. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
11. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology